Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same
US11987812B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 26, 2019 |
| Grant date | May 21, 2024 |
| Priority date | — |
| Expiry date | Sep 2, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/2302
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an immunocyte having higher cytotoxic activity, and a pharmaceutical composition for NK cell therapies, for which high effect can be expected. The present invention provides a cell population including CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells. The present invention provides the cell population, wherein the CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells further highly express CD11c. The present invention provides a CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cell, which infiltrates into a solid tumor. The present invention also provides a pharmaceutical composition containing such a cell population and a pharmaceutically acceptable additive. The present invention further provides a method for producing the aforementioned cell population.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.